|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOL11 |
Gene summary for NOL11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOL11 | Gene ID | 25926 |
| Gene name | nucleolar protein 11 | |
| Gene Alias | NOL11 | |
| Cytomap | 17q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q9H8H0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25926 | NOL11 | LZE4T | Human | Esophagus | ESCC | 1.88e-04 | 3.40e-01 | 0.0811 |
| 25926 | NOL11 | LZE7T | Human | Esophagus | ESCC | 1.81e-07 | 5.04e-01 | 0.0667 |
| 25926 | NOL11 | LZE20T | Human | Esophagus | ESCC | 1.03e-07 | 1.29e-01 | 0.0662 |
| 25926 | NOL11 | LZE22T | Human | Esophagus | ESCC | 2.12e-03 | 3.48e-01 | 0.068 |
| 25926 | NOL11 | LZE24T | Human | Esophagus | ESCC | 2.13e-13 | 3.31e-01 | 0.0596 |
| 25926 | NOL11 | LZE21T | Human | Esophagus | ESCC | 2.02e-02 | 2.66e-01 | 0.0655 |
| 25926 | NOL11 | LZE6T | Human | Esophagus | ESCC | 3.88e-04 | 1.54e-01 | 0.0845 |
| 25926 | NOL11 | P1T-E | Human | Esophagus | ESCC | 4.22e-03 | 3.05e-01 | 0.0875 |
| 25926 | NOL11 | P2T-E | Human | Esophagus | ESCC | 3.90e-27 | 5.55e-01 | 0.1177 |
| 25926 | NOL11 | P4T-E | Human | Esophagus | ESCC | 3.37e-12 | 3.71e-01 | 0.1323 |
| 25926 | NOL11 | P5T-E | Human | Esophagus | ESCC | 1.72e-26 | 6.91e-01 | 0.1327 |
| 25926 | NOL11 | P8T-E | Human | Esophagus | ESCC | 8.68e-20 | 3.88e-01 | 0.0889 |
| 25926 | NOL11 | P9T-E | Human | Esophagus | ESCC | 7.65e-11 | 2.54e-01 | 0.1131 |
| 25926 | NOL11 | P10T-E | Human | Esophagus | ESCC | 9.19e-28 | 4.52e-01 | 0.116 |
| 25926 | NOL11 | P11T-E | Human | Esophagus | ESCC | 3.00e-14 | 8.41e-01 | 0.1426 |
| 25926 | NOL11 | P12T-E | Human | Esophagus | ESCC | 4.48e-35 | 6.14e-01 | 0.1122 |
| 25926 | NOL11 | P15T-E | Human | Esophagus | ESCC | 2.20e-19 | 5.36e-01 | 0.1149 |
| 25926 | NOL11 | P16T-E | Human | Esophagus | ESCC | 5.25e-33 | 5.13e-01 | 0.1153 |
| 25926 | NOL11 | P17T-E | Human | Esophagus | ESCC | 2.34e-09 | 2.59e-01 | 0.1278 |
| 25926 | NOL11 | P20T-E | Human | Esophagus | ESCC | 8.95e-16 | 4.66e-01 | 0.1124 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000636421 | Liver | HCC | rRNA processing | 185/7958 | 225/18723 | 8.14e-35 | 6.45e-32 | 185 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:004227422 | Liver | HCC | ribosomal small subunit biogenesis | 65/7958 | 73/18723 | 1.09e-16 | 9.92e-15 | 65 |
| GO:00304901 | Liver | HCC | maturation of SSU-rRNA | 43/7958 | 50/18723 | 2.35e-10 | 8.04e-09 | 43 |
| GO:0009303 | Liver | HCC | rRNA transcription | 25/7958 | 34/18723 | 2.42e-04 | 1.81e-03 | 25 |
| GO:0006360 | Liver | HCC | transcription by RNA polymerase I | 36/7958 | 55/18723 | 4.94e-04 | 3.23e-03 | 36 |
| GO:0006356 | Liver | HCC | regulation of transcription by RNA polymerase I | 24/7958 | 34/18723 | 8.62e-04 | 5.13e-03 | 24 |
| GO:0045943 | Liver | HCC | positive regulation of transcription by RNA polymerase I | 16/7958 | 23/18723 | 8.04e-03 | 3.17e-02 | 16 |
| GO:0098781 | Liver | HCC | ncRNA transcription | 33/7958 | 56/18723 | 9.64e-03 | 3.63e-02 | 33 |
| GO:0042790 | Liver | HCC | nucleolar large rRNA transcription by RNA polymerase I | 13/7958 | 18/18723 | 1.05e-02 | 3.89e-02 | 13 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:000636410 | Oral cavity | OSCC | rRNA processing | 172/7305 | 225/18723 | 1.57e-30 | 1.24e-27 | 172 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:001607210 | Oral cavity | OSCC | rRNA metabolic process | 176/7305 | 236/18723 | 6.51e-29 | 3.24e-26 | 176 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:004227420 | Oral cavity | OSCC | ribosomal small subunit biogenesis | 63/7305 | 73/18723 | 7.61e-17 | 6.34e-15 | 63 |
| GO:00304903 | Oral cavity | OSCC | maturation of SSU-rRNA | 41/7305 | 50/18723 | 5.59e-10 | 1.46e-08 | 41 |
| GO:00987811 | Oral cavity | OSCC | ncRNA transcription | 38/7305 | 56/18723 | 1.15e-05 | 1.18e-04 | 38 |
| GO:00063563 | Oral cavity | OSCC | regulation of transcription by RNA polymerase I | 25/7305 | 34/18723 | 4.63e-05 | 3.90e-04 | 25 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOL11 | SNV | Missense_Mutation | c.1687N>A | p.Glu563Lys | p.E563K | Q9H8H0 | protein_coding | tolerated(0.57) | benign(0) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| NOL11 | SNV | Missense_Mutation | novel | c.1337N>G | p.Ala446Gly | p.A446G | Q9H8H0 | protein_coding | deleterious(0.04) | benign(0.188) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| NOL11 | SNV | Missense_Mutation | c.19N>C | p.Glu7Gln | p.E7Q | Q9H8H0 | protein_coding | tolerated(0.25) | benign(0.188) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| NOL11 | SNV | Missense_Mutation | novel | c.1646G>T | p.Gly549Val | p.G549V | Q9H8H0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NOL11 | SNV | Missense_Mutation | c.1524N>G | p.Phe508Leu | p.F508L | Q9H8H0 | protein_coding | deleterious(0.01) | benign(0.026) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| NOL11 | SNV | Missense_Mutation | novel | c.769G>A | p.Gly257Ser | p.G257S | Q9H8H0 | protein_coding | deleterious(0.03) | possibly_damaging(0.554) | TCGA-C8-A1HE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NOL11 | deletion | Frame_Shift_Del | novel | c.725delA | p.Asn242IlefsTer4 | p.N242Ifs*4 | Q9H8H0 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| NOL11 | SNV | Missense_Mutation | rs755793736 | c.785N>C | p.Gly262Ala | p.G262A | Q9H8H0 | protein_coding | tolerated(0.35) | possibly_damaging(0.48) | TCGA-C5-A8XH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| NOL11 | SNV | Missense_Mutation | c.451G>A | p.Glu151Lys | p.E151K | Q9H8H0 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| NOL11 | SNV | Missense_Mutation | novel | c.1176G>T | p.Gln392His | p.Q392H | Q9H8H0 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |